BioTech

Gilead Sciences To Acquire Arcellx

February 23, 2026 — 06:21 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Gilead Sciences (GILD) has entered into a definitive agreement to acquire Arcellx (ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Gilead currently owns approximately 11.5 percent of Arcellx's outstanding common stock.

Kite, a Gilead company, and Arcellx have an existing collaboration to co-develop and co-commercialize Arcellx's lead pipeline candidate, anitocabtagene autoleucel or anito-cel. The CVR entitles the holder to receive an additional $5 per CVR upon the achievement of cumulative global net sales of anito-cel of at least $6.0 billion from launch through year-end 2029.

Gilead Sciences said, upon FDA approval of anito-cel, the proposed transaction is expected to be accretive to earnings per share in 2028 and thereafter.

In pre-market trading on NasdaqGS, Arcellx shares are up 77.69 percent to $113.92.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Gilead Sciences To Acquire Arcellx

Tags

Latest Articles